Mydecine Innovations today announced it entered a definitive share exchange agreement to acquire 100% of NeuroPharm. Mydecine Innovations will acquire all issued and outstanding shares in the capital of NeuroPharm for $6 million, which will be payable in common shares in the capital of the company. NeuroPharm is currently developing evidence-based medicine of psychedelic based…